摘要
目的为了进一步探究噻托溴铵联合福莫特罗布地奈德对COPD的临床治疗效果,完善临床对慢性阻塞性肺疾的药物治疗方案。方法方便选取青岛市胶州中心医院2013年1月—2016年1月所收治的190例COPD患者的临床治疗资料,采用随机分组方式将全部患者分为对照组A(单纯使用复方异丙托溴铵)和对照组B(联合使用噻托溴铵与福莫特罗布地奈德),每组各有患者95例,两组患者均采用常规基础治疗,观察期均为6个月,对比两组患者的治疗效果、住院时间、气血改善情况、不良反应等。结果对照组B治疗总有效率为92.63%,对照组A治疗总有效率为83.16%,对照组B明显优于对照组A,差异有统计学意义(P<0.05)。对照组B住院时间为(6.47±2.24)d,对照组A为(11.71±3.71)d,且对比两组患者PaO_2、PaCO_2改善情况,对照组B明显优于对照组A,差异有统计学意义(P<0.05)。治疗后,对照组A患者的PaO_2与PaCO_2分别为(69.59±2.07)、(36.52±3.26)mm Hg;对照组B患者的PaO_2与PaCO_2分别为(78.38±3.26)、(40.23±2.81)mm Hg,差异有统计学意义(P<0.05)。另外,对照组A不良反应出现概率为8.42%,对照组B不良反应出现概率为5.26%,对比两组患者不良反应发生情况差异无统计学意义(P>0.05)。结论 COPD具有显著的病理特征,对患者社会行为具有明显的负面影响,联合使用噻托溴铵与福莫特罗布地奈德具有理想的临床治疗效果,且药物起效快、药效明显、持续时间长、不良反应小,应于临床重点推广。
Objective This paper tries to further explore the efficacy of tiotropium in combination with formoterol and budesonide in the treatment of COPD,improve the clinical treatment of chronic obstructive pulmonary disease drug treatment.Methods The clinical data of 190 cases of COPD patients in this hospital from January 2013 to January 2016 were conveniently selected and were randomly grouped,all patients can be divided into control group A(simply using compound isopropyl bromide)and control group B(combination of tiotropium and formoterol budesonide),each group had 95 patients,two groups of patients were used conventional foundation treatment,observation period of 6 months,comparison of the two groups of patients with treatment,hospital stay,qi and blood to improve the situation,adverse reactions.Results In the control group B,the total effective rate was 92.63%,the total effective rate was 83.16%in the control group A,and the control group B was significantly better than the control group A,with statistical difference(P<0.05).In the control group B,the time of hospitalization was(6.47±2.24)d,and the control group A was(11.71±3.71)d,and the improvement of PaO2 and PaCO2 in the two groups,the control group B was significantly better than the control group A,with statistical difference(P<0.05).After treatment,PaO2 and PaCO2 in control group A were respectively(69.59±2.07),(36.52±3.26)mmHg.The PaO2 and PaCO2 in the control group B were respectively(78.38±3.26),(40.23±2.81)mmHg,with statistical difference(P<0.05).In addition,the adverse reaction occurrence probability in control group A was 8.42%,the control group B was 5.26%,so the adverse reaction conditions had no statistical difference(P>0.05).Conclusion COPD has significant pathological features,which have a significant negative impact on social behavior of patients.Combined use of tiotropium and formoterol budesonide has an ideal clinical therapeutic effect,and the drug has the advantages of rapid onset,obvious efficacy and long duration,small side effects,wh
作者
张蕾
ZHANG Lei(Department of Respiratory Medicine,Rizhao People’s Hospital,Rizhao,Shandong Province,276800 China)
出处
《中外医疗》
2017年第36期143-145,共3页
China & Foreign Medical Treatment
关键词
慢性阻塞性肺疾病
噻托溴铵
福莫特罗布地奈德
复方异丙托溴铵
临床研究
Chronic obstructive pulmonary disease
Tiotropium bromide
Formoterol desonide
Compound ipratropium bromide
Clinical study
